List of Baqsimi drug patents

Baqsimi is owned by Eli Lilly And Co.

Baqsimi contains Glucagon.

Baqsimi has a total of 4 drug patents out of which 1 drug patent has expired.

Expired drug patents of Baqsimi are:

  • US6938798

Baqsimi was authorised for market use on 24 July, 2019.

Baqsimi is available in powder;nasal dosage forms.

Baqsimi can be used as treatment of severe hypoglycemia in patients with diabetes.

The generics of Baqsimi are possible to be released after 23 September, 2039.

BAQSIMI's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6938798 ELI LILLY AND CO Fluid or powdery product dispensing device
Jan, 2022

(1 year, 4 months ago)

US10213487 ELI LILLY AND CO Nasal powder formulation for treatment of hypoglycemia
Feb, 2036

(12 years from now)

US10894133 ELI LILLY AND CO Device for dispensing a fluid product
Jan, 2038

(14 years from now)

US10765602 ELI LILLY AND CO Medication delivery systems and methods
Sep, 2039

(16 years from now)

Do you want to check out BAQSIMI patents from before 2022?
Exclusivity Exclusivity Expiration
New Product (NP) Jul 24, 2022

Drugs and Companies using GLUCAGON ingredient

Market Authorisation Date: 24 July, 2019

Treatment: Treatment of severe hypoglycemia in patients with diabetes

Dosage: POWDER;NASAL

More Information on Dosage

BAQSIMI family patents

8

United States

7

European Union

6

Japan

4

China

4

France

3

Morocco

3

Australia

2

Canada

2

South Africa

1

Spain

1

Dominican Republic

1

Philippines

1

Malaysia

1

Moldova, Republic of

1

Denmark

1

RS

1

Poland

1

Germany

1

Brazil

1

Ukraine

1

Singapore

EA

1

EA

1

New Zealand

1

Croatia

1

Korea, Republic of

1

Guatemala

1

Cyprus

1

Peru

1

Chile

1

Israel

1

Portugal

1

El Salvador

1

Mexico

1

Costa Rica

1

Ecuador

1

Colombia

1

Lithuania

1

Saudi Arabia

1

Tunisia

1

Slovenia

1

Hungary

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in